Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous disease with at least five molecular subtypes characterized by distinct gene expression, genomic and tumor microenvironment (TME) profiles. The phase III adjuvant IBCSG 22-00 trial evaluating low-dose cyclophosphamide and methotrexate (CM) chemotherapy did not show a clinical benefit in unselected TNBC patients. Here, we aimed to explore whether specific TNBC molecular subtypes and TME features could predict benefit to low-dose CM maintenance chemotherapy in the IBCSG 22-00 study.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
